Aspirin versus low-molecular-weight heparin after total hip arthroplasty

Annals of Internal Medicine

Volumn 159, Issue 7, 2013, Pages 502-503

  Granziera, Serena ^a   Cohen, Alexander T ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

BLEEDING; DEEP VEIN THROMBOSIS; HUMAN; LETTER; LUNG EMBOLISM; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM; FEMALE; HIP ARTHROPLASTY; MALE; NOTE;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ASPIRIN; DALTEPARIN; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; VENOUS THROMBOEMBOLISM;

EID: 84884854650     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-159-7-201310010-00017     Document Type: Letter

References (5)

1. Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013;158:800-6. [PMID: 23732713]
2. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355:1295-302. [PMID: 10776741]
3. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:7S-47S. [PMID: 22315257]
4. Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a doubleblind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med. 2000;160:2208-15. [PMID: 10904465]
5. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-75. [PMID: 18579811]